QuidelOrtho Corporation Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Oct-2026Ownership Structure
Ownership Analysis
Nobody can force a decision at QuidelOrtho. BlackRock's 16.3% sits in index and model portfolios, and the next two holders, FMR at 11.5% and Newtyn at 9.7%, are active investors who can vote against directors but cannot name any. We weigh Newtyn most heavily of the three, because it added 2,066,528 shares between March 31 and June 30, yet it files the passive Schedule 13G, which certifies no purpose of seeking control.Governance changed in November 2024. Until then Carlyle held two board seats under a stockholders agreement, and the agreement lapsed when its last shares were sold, so both Carlyle directors resigned. Two independent directors joined in December 2024. We hold that the board which approved the LEX purchase and then watched the 2026 guidance fall had no sponsor in the room, so nobody can blame a controlling holder for its choices. The company replaced its previous chief executive, Douglas Bryant, in February 2024. We are wary of crediting Blaser with a clean slate. He took over in May 2024, and the stock is now 64% below the price Carlyle accepted that November.Insider ownership is thin. Blaser's 85,974 shares are worth just over $1 million at $12.45, and his May sale of 10,252 shares at $10.32 only covered tax withholding. Directors must hold five times their cash retainer, which is $375,000 on the $75,000 standard retainer and $750,000 for the $150,000 chair. If the chair and eight other outside directors sat exactly at that floor, the board would own $3.75 million in all, 0.44% of the company. We discount those guidelines as alignment, because a 63% fall in a year makes minimum holdings cheap. Busky bought 3,370 shares in February 2026 and was gone by July, and we give that purchase no weight as a signal.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Seven institutions together hold about 59% of the shares. BlackRock's 16.3%, FMR's 11.5%, Newtyn's 9.7%, Vanguard Portfolio Management's 6.0%, Vanguard Capital Management's 5.2%, Neuberger Berman's 5.2% and Invesco's 5.1% leave only about 41% for everyone else. Trading is thin against that concentration: 789,306 shares changed hands on September 29, a turnover of 1.2% in a day.We give little weight to the idea that Vanguard's two filers are two voices. Vanguard Group's own 13G/A, with an event date of March 13, 2026, reported zero shares because its units now file separately. Together they hold 7,660,731 shares, which we total at 11.2%, and both are index driven.The flows are more informative than the totals. Newtyn's reported position grew from 4,558,472 shares at March 31 to 6,625,000 at June 30, a 45% increase in one quarter. Invesco barely moved, from 3,470,656 to 3,473,432. Jana Partners sold its entire stake between July and September 2024. Rubric's 5.56% from year-end does not appear in the mid-2026 filings we found, and we cannot say whether it sold.On valuation, enterprise value is about $3.62 billion: $853.8 million of equity plus $2.891 billion of debt less $123.4 million of cash. Against adjusted EBITDA guidance of $540 million at the low end and $560 million at the high end, that is 6.6 times the $550 million midpoint. Each 0.1 turn of multiple moves equity by $55 million, or $0.80 a share, and each $10 million of EBITDA moves it by about $66 million, or $0.96. We reckon that leverage explains why a modest guidance cut produced so large a share price fall: the equity is about 24% of enterprise value.Sentiment is bleak. Short interest equals 20.7% of the shares available for trading, three analysts rate the stock Hold, and the $14.67 average target sits 17.8% above the price. Book equity of $1.775 billion is 2.1 times the market value, which we take as the market pricing in further write-downs.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Quidel Corporation | Subsidiary | Original San Diego rapid testing business founded in 1979 and the legal parent of the combination until 2022 |
| Ortho Clinical Diagnostics | Subsidiary | Laboratory and transfusion medicine business acquired in 2022 that sells to hospital and reference labs in more than 140 countries |
| VITROS | Brand | Ortho line of clinical chemistry and immunoassay analyzers and reagents sold to laboratories |
| ORTHO VISION | Brand | Ortho immunohematology analyzers used for blood typing and screening in transfusion services |
| Sofia | Brand | Quidel fluorescence reader platform whose SARS antigen test won the first FDA emergency authorization for a COVID-19 rapid antigen test |
| QuickVue | Brand | Quidel lateral flow rapid tests for infectious disease sold to clinics and pharmacies |
| TRIAGE | Brand | Cardiovascular and toxicology testing line bought from Alere in 2017 and run on the Triage MeterPro |
| LEX Diagnostics | Subsidiary | Maker of the LEX VELO ultra fast PCR system for influenza A and B and COVID-19 acquired in April 2026 |
Portfolio Analysis
Labs earned $1.51 billion in 2025, up 5.5% and 55% of revenue, with Immunohematology at $543.8 million and Point of Care at $601.6 million, down 13.4%. TRIAGE brought in $132.7 million, up 8.9%. The second-quarter 2026 figures only reconcile if TRIAGE is counted inside Point of Care. Labs $383 million, Immunohematology $134 million, Point of Care $108 million, Molecular $1.6 million and Donor Screening $4 million sum to $630.6 million of the $631 million reported.Strip TRIAGE out and the rest of Point of Care fell 18.1%, from about $572.8 million down to $468.9 million. We judge that decline to be the respiratory test hangover rather than weak share, since COVID-19 testing revenue fell to $80.2 million from $184.9 million, now 2.9% of sales.Geography now carries the larger risk. China was 12% of 2025 revenue, and in the second quarter it brought in $67.8 million, down 23.3% at constant currency, while Labs in China fell 24.2%. Management blames proposed pricing guidelines for in vitro diagnostics and does not expect improvement soon. At the quarter's run rate China is about $271 million a year, and each further 10% decline would remove about $27 million of revenue. Outside China, revenue grew 6%.The guidance cut is arithmetic on these pieces. First-half 2026 revenue was $1,250.7 million. The new range of $2.52 billion to $2.60 billion therefore implies a second half of $1.27 billion to $1.35 billion, against about $1.43 billion a year earlier. By our arithmetic the implied fall is 6% to 11%. We insist on reading it as a forecast for China and respiratory demand. It says little about the Labs franchise.Molecular was $26.5 million in 2025 and is where LEX VELO would land. Donor Screening was roughly $48 million in 2025 by our subtraction, and we would put the run rate after the Grifols exit near $16 million.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| QuidelOrtho Corporation ★ | N/A | $2.73B FY2025 | Recurring reagent revenue from a large installed base of lab and transfusion analyzers |
| Abbott Laboratories | N/A | $8.94B FY2025 diagnostics | Largest core lab and rapid test franchise with a deep installed base |
| Roche | N/A | CHF 13.8B FY2025 diagnostics | Global leader in lab automation and molecular testing |
| Danaher | N/A | $9.94B FY2025 diagnostics | Owner of Beckman Coulter and Cepheid with a broad lab and molecular portfolio |
| bioMerieux | N/A | EUR 4.07B FY2025 | Microbiology and BIOFIRE syndromic panel specialist with fast growing SPOTFIRE |
Competitive Analysis
QuidelOrtho competes against divisions of much larger groups. Abbott's Diagnostics sales were $8.937 billion in 2025 and Danaher's Diagnostics segment, which holds Beckman Coulter, was $9.941 billion, so each is about 3.3 and 3.6 times QuidelOrtho's $2.73 billion. Roche's Diagnostics division sold CHF 13.8 billion. Only bioMerieux, at EUR 4.07 billion, is within two times. Diagnostics is also a smaller part of those parents, at 20% of Abbott's total and 40% of Danaher's, whereas QuidelOrtho has no other business to cross-subsidise it.Direct comparisons favour QuidelOrtho in the lab and not at the point of care. Abbott's Core Laboratory grew 2.1% organically to $5.36 billion, against 5.5% for QuidelOrtho Labs. In rapid testing the order reverses: Abbott's Rapid Diagnostics fell 18.0% organically to $2.454 billion and QuidelOrtho's own rapid-test line lost 13.4%, a similar slide. We rank QuidelOrtho's lab franchise ahead of Danaher's, whose Diagnostics grew 1.5%, and ahead of Siemens Healthineers' Diagnostics, which was flat in its fourth quarter at a 7.5% adjusted EBIT margin. Adjusted EBITDA margin of 21.9% is a different measure, so we do not set it against those margins.The threat is molecular. bioMerieux's SPOTFIRE reached EUR 168 million of sales in 2025 after growing 84%, in the same respiratory pool as LEX VELO, while QuidelOrtho's whole Molecular line took in $26.5 million. bioMerieux also earns a 17.9% operating margin before non-recurring items on sales that grew 6.2% organically. We discount management's hopes of LEX adding to profit in 2027 and 2028 until an installed base appears. Danaher is both rival and customer, since Beckman owes Quidel at least $70 million annually, so we expect a commercial rather than hostile relationship. Siemens Healthineers, with EUR 23.4 billion of group revenue and about 74,000 staff, is the one peer we cannot size on diagnostics alone.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Ortho Clinical Diagnostics | $6.00B | 2022 | Laboratory and transfusion medicine business combined with Quidel after an announced offer of $24.68 per Ortho share |
| Alere Triage and BNP assets | $400.0M | 2017 | Cardiovascular Triage line and BNP assay business bought with up to $40M of contingent payments |
| LEX Diagnostics | $174.6M | 2026 | Maker of the LEX VELO point of care PCR system including a prior stake and a capped earn out |
| Diagnostic Hybrids | $130.0M | 2010 | Ohio maker of cell culture based viral diagnostics bought by Quidel |
| BioHelix Corporation | undisclosed | 2013 | Massachusetts molecular technology developer bought by Quidel |
Acquisitions Analysis
The LEX purchase shows how little cash a $174.6 million headline can involve. QuidelOrtho paid $98.6 million in cash, credited $41.0 million for the stake it already held from December 2023, and recorded a $35.0 million earn-out. The earn-out pays 5% of net revenue between April 2029 and March 2035, so reaching the cap needs $700 million of LEX revenue in that window. Intangibles of $208.1 million plus $5.7 million of other assets, less $36.4 million of deferred tax, come to $177.4 million, within $2.8 million of the price, which leaves essentially no goodwill. We weigh that as a clean allocation, and our own check found no gap. We see the risk in the intangibles, and in dropping the company's own SAVANNA platform to buy a rival design.Ortho cost about $6 billion. Ortho holders were offered $24.68 a share, a 25% premium to the December 22, 2021 close, and Quidel promised $90 million of cost synergies by year three plus more than $100 million of cross-selling revenue by 2025. Cost savings reached $140 million by the end of 2025, beating the target by 1.6 times. We insist on separating that from the revenue goal, because the top line shrank and a $700.7 million goodwill write-down arrived in the third quarter of 2025, which is the accountants' verdict on price.The 2017 Alere deal returned money faster. Quidel paid $400 million plus up to $40 million for TRIAGE and the BNP assay business. TRIAGE alone still sells $132.7 million a year, so the $400 million base price equals about three years of its current sales, and Beckman's minimum $70 million a year equals 17.5% of that price.Diagnostic Hybrids ($130 million, 2010) and BioHelix (2013, price undisclosed) are small beside those. We total the four disclosed prices at about $6.7 billion, and 90% of that is one deal.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
The Ortho exchange terms looked better than they turned out. Ortho holders received $7.14 in cash plus 0.1055 QuidelOrtho shares for each Ortho share, while Quidel holders received one share for one. At the $98.38 intraday price on closing day, the package was worth $17.52, which is 29% below the $24.68 announced. Quidel shares had already fallen 17.8% on the day of announcement.Carlyle's exit came in pieces. After small sales in the summer of 2024 it sold its last 8.26 million shares in November, raising about $291.7 million through Goldman Sachs as sole underwriter, with no shares offered by the company. Buyers at that $35.314 are down 64.7% at $12.45, and holders from the May 2022 close are down 87.3%. We reckon the sell-down, not any business event, lifted the overhang,. Our tally of the buyers' loss uses only the two prices, and we do not adjust it for dividends because none were paid.Exits followed. The company announced the end of SAVANNA development in the second quarter of 2025, impaired its Raritan, New Jersey plant by $10 million in the third quarter, and says it eliminated about 12% of the organization under Blaser. Restructuring, integration and other charges were $263.6 million in fiscal 2025, equal to 9.7% of revenue. The first half of 2026 added $10.9 million, with $6.5 million in the second quarter alone.The Grifols joint business closed at the start of 2026. We judge that shareholders absorbed the cost twice, once in the $65.0 million charge and again in lost profit share, which was $20.9 million for the first half of 2025. We set the $263.6 million of fiscal 2025 restructuring charges against $140 million of cumulative annualized savings, and the charges are 1.9 times larger.
Ownership History
Ownership History Analysis
QuidelOrtho's ownership has moved from a founder-era small cap, to a sponsor-held private company, to a widely held one. David H. Katz founded Quidel in 1979, and its first products reached the market in 1984. In 2020 its Sofia 2 SARS antigen test became the first COVID-19 rapid antigen test to win an FDA emergency authorization. Carlyle bought Ortho from Johnson & Johnson for $4.15 billion in 2014 and held it for a decade. We give full weight to the November 2024 date when the sponsor finished selling: from then on the shareholder list is institutions alone, about 235 of them by one tracker.The record since is one of shrinkage. The share price has fallen 87.3% from the $98.38 closing-day print, while employees went from 7,100 in 2023 to 6,500 in 2025, a cut of 8.5%, and revenue slid 9%. The share count barely moved, from 67,931,540 on October 29, 2025 to 68,575,427 on July 29, 2026, a 0.9% increase, so dilution has not been the cause. Hedge fund money has come and gone, with Jana buying and selling inside 2024 and Newtyn raising its stake to 9.7% in 2026. We hold that ownership is now being set by funds buying a leveraged recovery, and we reckon their patience depends on whether $2.891 billion of debt allows them to wait. Our count of sponsor years is ten, out of more than four decades, so we do not treat the sponsor period as the defining one. The defining feature is leverage: the two term loans now matter more to the equity than any shareholder vote does. We insist on that ordering because the $2.891 billion balance leaves the company little room to pay out cash.
Ownership Explained
QuidelOrtho Corporation, a diagnostics maker headquartered at 9975 Summers Ridge Road in San Diego, had 68,575,427 common shares outstanding on July 29, 2026. They trade on Nasdaq under QDEL. At $12.45 on October 6 the equity was worth about $853.8 million, against $98.38 a share on May 27, 2022, the day Quidel and Ortho Clinical Diagnostics combined. Carlyle no longer holds a stake, and no holder reports a board seat.Asset managers hold most of the stock. BlackRock reported 11.2 million shares in its June 30 13F, which works out to 16.3%. FMR LLC, the Fidelity parent, filed for 7,852,322 shares, or 11.5%. Newtyn Management reported 6,625,000 shares at June 30, or 9.7%. Vanguard files through two units: Vanguard Portfolio Management with 4,088,168 shares (6.0%) and Vanguard Capital Management with 3,572,563 (5.2%). Neuberger Berman holds 3,534,619 shares (5.2%) and Invesco 3,473,432 (5.1%). Rubric Capital Management reported 3,777,157 shares, or 5.56%, as of December 31, 2025.Brian J. Blaser has been President and Chief Executive Officer since May 2024. After a May 15, 2026 vesting of restricted stock he owned 85,974 shares, 45,901 directly and 40,073 through a trust, about 0.13% of the total. Micah Young, formerly chief financial officer of Masimo, became chief financial officer on July 6, 2026 when Joseph Busky retired. The board had 11 directors in April and 10 once Matthew W. Strobeck stepped down on June 16.The business traces to Quidel, which David H. Katz founded in 1979, and to Ortho, which joined in 2022. The 10-K counts about 6,500 employees and reports five geographic segments: North America, EMEA, China, JPAC and Latin America. Fiscal 2025 revenue was $2.73 billion, and the company sorts it into Labs, Immunohematology, Point of Care, Molecular Diagnostics and Donor Screening.
The credit agreement is the contract that binds hardest. QuidelOrtho owed $2.891 billion at June 28, 2026, under a facility with a $1.15 billion Term Loan A, a $1.45 billion Term Loan B and a $700 million revolver. It drew $100 million of the revolver on April 13 to fund LEX Diagnostics. Net debt stood at 4.9 times adjusted EBITDA, or 4.3 times on the pro forma definition in the agreement, and first-half interest expense was $106 million.A 2021 settlement with Beckman Coulter, the Danaher unit, sends cash the other way. Beckman agreed to pay Quidel between $70 million and $75 million a year through 2029, with a $17.5 million quarterly floor, while Quidel keeps supplying the antibodies behind the BNP heart-failure assay that Beckman now sells under its own label.The Grifols contract ran the opposite direction. Ortho's joint business with Grifols in hepatitis and HIV screening ended on January 1, 2026. QuidelOrtho booked a $65.0 million charge in fiscal 2025, payable over three years, and paid $25 million of it in the second quarter. Donor Screening revenue fell from $13.3 million to $4.0 million in that quarter.LEX Diagnostics' former holders hold a claim of their own: 5% of LEX net revenue from April 1, 2029 to March 31, 2035, capped at $35.0 million.Customer contracts anchor the revenue. The company serves about 75,000 customers, reports a 95% average contract renewal rate, and counts about 145,000 cumulative instrument placements. More than 95% of revenue is recurring assays, reagents, consumables and services.Shareholders sit behind all of this. Securities class actions naming the company and certain executives have been filed since April 2024, and the shares are down 57.5% in 2026.